Cargando…
Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
OBJECTIVE—The aim of this study was to examine the effect of protein kinase Cβ inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subj...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606837/ https://www.ncbi.nlm.nih.gov/pubmed/18945921 http://dx.doi.org/10.2337/dc08-1609 |
_version_ | 1782162992767434752 |
---|---|
author | Cherney, David Z.I. Konvalinka, Ana Zinman, Bernard Diamandis, Eleftherios P. Soosaipillai, Anton Reich, Heather Lorraine, Joanne Lai, Vesta Scholey, James W. Miller, Judith A. |
author_facet | Cherney, David Z.I. Konvalinka, Ana Zinman, Bernard Diamandis, Eleftherios P. Soosaipillai, Anton Reich, Heather Lorraine, Joanne Lai, Vesta Scholey, James W. Miller, Judith A. |
author_sort | Cherney, David Z.I. |
collection | PubMed |
description | OBJECTIVE—The aim of this study was to examine the effect of protein kinase Cβ inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subjects. RESEARCH DESIGN AND METHODS—Albuminuric subjects were randomized (2:1) to ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal hemodynamic function was measured during clamped euglycemia or hyperglycemia and before and after ruboxistaurin or placebo. RESULTS—Ruboxistaurin was not associated with between-group differences during clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperfilterers with normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, whereas the epidermal growth factor–to–MCP-1 ratio increased in hyperfilterers versus normofilterers (all P < 0.05). CONCLUSIONS—The effect of ruboxistaurin is modest and dependent, at least in part, on the level of ambient glycemia and baseline glomerular filtration rate. |
format | Text |
id | pubmed-2606837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-26068372010-01-01 Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study Cherney, David Z.I. Konvalinka, Ana Zinman, Bernard Diamandis, Eleftherios P. Soosaipillai, Anton Reich, Heather Lorraine, Joanne Lai, Vesta Scholey, James W. Miller, Judith A. Diabetes Care Emerging Treatments and Technologies OBJECTIVE—The aim of this study was to examine the effect of protein kinase Cβ inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subjects. RESEARCH DESIGN AND METHODS—Albuminuric subjects were randomized (2:1) to ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal hemodynamic function was measured during clamped euglycemia or hyperglycemia and before and after ruboxistaurin or placebo. RESULTS—Ruboxistaurin was not associated with between-group differences during clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperfilterers with normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, whereas the epidermal growth factor–to–MCP-1 ratio increased in hyperfilterers versus normofilterers (all P < 0.05). CONCLUSIONS—The effect of ruboxistaurin is modest and dependent, at least in part, on the level of ambient glycemia and baseline glomerular filtration rate. American Diabetes Association 2009-01 /pmc/articles/PMC2606837/ /pubmed/18945921 http://dx.doi.org/10.2337/dc08-1609 Text en Copyright © 2009, American Diabetes Association https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Emerging Treatments and Technologies Cherney, David Z.I. Konvalinka, Ana Zinman, Bernard Diamandis, Eleftherios P. Soosaipillai, Anton Reich, Heather Lorraine, Joanne Lai, Vesta Scholey, James W. Miller, Judith A. Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study |
title | Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
|
title_full | Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
|
title_fullStr | Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
|
title_full_unstemmed | Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
|
title_short | Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study
|
title_sort | effect of protein kinase cβ inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study |
topic | Emerging Treatments and Technologies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606837/ https://www.ncbi.nlm.nih.gov/pubmed/18945921 http://dx.doi.org/10.2337/dc08-1609 |
work_keys_str_mv | AT cherneydavidzi effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT konvalinkaana effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT zinmanbernard effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT diamandiseleftheriosp effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT soosaipillaianton effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT reichheather effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT lorrainejoanne effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT laivesta effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT scholeyjamesw effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy AT millerjuditha effectofproteinkinasecbinhibitiononrenalhemodynamicfunctionandurinarybiomarkersinhumanswithtype1diabetesapilotstudy |